Advertisement

Myelin basic protein and S-100 antigen in cerebrospinal fluid of patients with multiple sclerosis in the acute phase

  • Massaro A. R. 
  • Michetti F. 
  • Laudisio A. 
  • Bergonzi P. 
Original Articles

Abstract

It has previously been demonstrated that both Myelin Basic Protein (MBP) and S-100 are released in the cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients during acute phases of exacebation of the disease. In order to investigate the pathobiological significance of the release of these two proteins into the CSF, MBP and S-100 were assayed in 10 MS patients during the five weeks following onset of an acute exacerbation. MBP was detectable in CSF during the first three weeks after exacrebation, while S-100 was detectable during the entire period of observation, at least in some of the patients. MBP reached its highest CSF concentrations during the first two weeks while S-100 did so in the third week, decreasing thereafter. This difference in time of presence of MBP and S-100 in the CSF is probably due to the different biological origin, MBP being a marker of myelin sheath injury, and S-100, more probably, of astrocytic activity.

Key-Words

Multiple sclerosis cerebrospinal fluid myelin basic protein S-100 

Sommario

È stato precedentemente dimostrato che sia la proteina basica della mielina (PBM) che la S-100 vengono liberate nel liquido cefalo-rachidiano (LCR) durante in periodi di esacerbazione della sclerosi multipla (SM). Al fine di approfondire ulteriormente il significato patobiologico della liberazione di queste due proteine nel LCR abbiamo eseguito uno studio quantitativo di PBM e S-100 in dieci malati di SM durante un periodo di 5 settimane successive ad una ricaduta. La PBM è risultata dosabile durante le prime tre settimane, mentre la S-100 è risultata essere presente nel LCR durante l'intero periodo di osservazione, almeno in alcuni dei pazienti. La PBM ha raggiunto i suoi maggiroi livelli durante le prime due settimane. La S-100, invece, durante la terza settimana, dopo di che vi è stata una netta riduzione dei suoi livelli liquorali. Questa differenza nei tempi di presenza di PBM ed S-100 nel LCR è probabilmente dovuta alla differente origine biological delle due proteine. La PBM, infatti, è marcatrice di lesione della guaina mielinica, la S-100 invece, con più probabilità, di attività dellule astrocitarie.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Whitaker J.N.:Myelin encephalitogenic protein fragments in CSF of persons with multiple sclerosis. Neurology 27:911–920, 1977.PubMedGoogle Scholar
  2. [2]
    Cohen S.R., Brooks B.R., Herndon R.M., Jubelt B., McKhann G.M.:A diagnostic index of active demyelination: myelin basic protein in CSF. Ann. Neurol. 8:25–31, 1980.CrossRefPubMedGoogle Scholar
  3. [3]
    Michetti F., Massaro A.R., Murazio M.:The nervous system-specific S-100 antigen in CSF of multiple sclerosis patients. Neurosci. Letters 11: 171–175, 1979.CrossRefGoogle Scholar
  4. [4]
    Michetti F., Massaro A.R., Russo G., Rigon G.:The S-100 antigen in CSF as a possible index of cell injury in the nerous system. J. Neurol. Sci. 44:259–263, 1980.CrossRefPubMedGoogle Scholar
  5. [4]
    Michetti F., Massaro A.R., Russo G., Rigon G.:The S-100 antigen in CSF as a possible index of cell injury in the nervous system. J. Neurol. Sci. 44:259–263, 1980.CrossRefPubMedGoogle Scholar
  6. [5]
    Cicero T.J., Cowan W., Moore B.W., Suntzeff V.: The cellular localization of the two brainspecific proteins S-100 and 14.3.2. Brain Res. 18: 25–34, 1970CrossRefPubMedGoogle Scholar
  7. [6]
    Brown J.R., Beebe G.W., Kurtzke J.F et al.:The design of clinical studies to assess therapeutic efficacy in multiple sclerosis. Neurology 29:3–23, 1979.PubMedGoogle Scholar
  8. [7]
    Cohen S.R., McKhann G.M., Guarnieri M.:A RIA for myelin basic protein and its use for quantitative measurements. J. Neurochem. 25: 371–376, 1975.PubMedGoogle Scholar
  9. [8]
    Whitaker J.N.:personal communication.Google Scholar
  10. [9]
    Massaro A.R., Carbone C. et al.:manuscript in preparation.Google Scholar
  11. [10]
    Moore W., Perez V.J.:Complement fixation for antigens at a picogram level. J. Immunol. 96: 100–1005, 1966Google Scholar
  12. [11]
    Moore B.W.:A soluble protein characteristic of the nervous system. Biochem. Biophys. Res. Commun. 19:739–744, 1965.CrossRefPubMedGoogle Scholar
  13. [12]
    Zuckermann J.E., Herschman H.R., Levine L.:Appearance of brain-specific antigen (the S-100 antigen) during human foetal development. J. Neurochem. 17:247–251, 1970.PubMedGoogle Scholar
  14. [13]
    Massaro A.R., Whitaker J.N., Michetti F.:S-100 antigen and MBP fragments in the CSF of MS patients for monitoring exacerbation phases of the disease. Acta Neurol. 37:270–271, 1982.Google Scholar
  15. [14]
    Massaro A.R., Michetti F., Gigli G.L.:Marker liquorali di danno del sistema nervoso centrale. pp. 147–158 in “L'Analisi Diagnostica del Liquor”, B. Tavolato and P. Livrea Eds.), Podova, Piccin, 1982.Google Scholar
  16. [15]
    Ludvin S.K., Kosek J.C., Eng L.F.:The topographic distribution of S-1000 and GFA proteins in the adult rat brain: immunohistochemical study using horseradish peroxidase labeled antibodies. J. comp. Neurol. 165: 197–208, 1976.CrossRefPubMedGoogle Scholar

Copyright information

© Masson Italia Periodici S.r.l. 1985

Authors and Affiliations

  • Massaro A. R. 
    • 2
  • Michetti F. 
    • 1
  • Laudisio A. 
    • 2
  • Bergonzi P. 
    • 2
  1. 1.Instituto di Anatomia dell'Università CattolicaRoma
  2. 2.Istituto di Neurologia dell'Università CattolicaRoma

Personalised recommendations